NCT03913091View on ClinicalTrials.gov

Liposomal Bupivacaine (Exparel ® ) Plus 0.5% Bupivacaine HCL Versus 0.5% Bupivacaine HCL for Interscalene Nerve Block (ISB) for Patients Undergoing Total Shoulder Arthroplasty(TSA)

PHASE4CompletedINTERVENTIONAL

Enrollment

184

Participants

Timeline

Start Date

March 1, 2019

Primary Completion Date

January 19, 2021

Study Completion Date

January 19, 2021

Conditions

Shoulder Pain

Interventions

DRUG

Liposomal Bupivacaine

Liposomal Bupivacaine Plus 0.5% Bupivacaine HCL

DRUG

0.5% Bupivacaine HCL

0.5% Bupivacaine HCL for Interscalene Nerve Block (ISB)

Trial Locations (1)

10016

NYU Langone Health, New York

All Listed Sponsors

lead

NYU Langone Health

OTHER

NCT03913091 - Liposomal Bupivacaine (Exparel ® ) Plus 0.5% Bupivacaine HCL Versus 0.5% Bupivacaine HCL for Interscalene Nerve Block (ISB) for Patients Undergoing Total Shoulder Arthroplasty(TSA) | Biotech Hunter | Biotech Hunter